GSK plc (NYSE:GSK) Shares Sold by M Holdings Securities Inc.

M Holdings Securities Inc. lessened its stake in GSK plc (NYSE:GSK – Get Rating) by 5.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,062 shares of the pharmaceutical company’s stock after selling 519 shares during the quarter. M Holdings Securities Inc.’s holdings in GSK were worth $267,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in GSK. Pflug Koory LLC acquired a new position in shares of GSK during the 3rd quarter valued at $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of GSK by 61.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after acquiring an additional 368 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC acquired a new position in shares of GSK during the 3rd quarter valued at $31,000. CoreCap Advisors LLC acquired a new position in shares of GSK during the 2nd quarter valued at $66,000. Finally, Zullo Investment Group Inc. lifted its holdings in shares of GSK by 21.3% during the 2nd quarter. Zullo Investment Group Inc. now owns 1,762 shares of the pharmaceutical company’s stock valued at $77,000 after acquiring an additional 309 shares in the last quarter. Institutional investors and hedge funds own 13.15% of the company’s stock.

GSK Price Performance

GSK opened at $33.58 on Thursday. The company has a 50-day moving average of $35.03 and a 200-day moving average of $33.55. The company has a market capitalization of $68.74 billion, a P/E ratio of 3.91, a PEG ratio of 1.68 and a beta of 0.65. GSK plc has a 1-year low of $28.47 and a 1-year high of $46.97. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.68 and a current ratio of 0.91.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 13th. Stockholders of record on Friday, February 24th will be issued a $0.3404 dividend. This represents a $1.36 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, February 23rd. GSK’s dividend payout ratio (DPR) is presently 15.50%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GSK shares. AlphaValue upgraded shares of GSK to a “buy” rating in a report on Thursday, December 8th. The Goldman Sachs Group initiated coverage on shares of GSK in a research note on Sunday, February 26th. They set a “buy” rating on the stock. TheStreet raised shares of GSK from a “c+” rating to a “b-” rating in a research note on Friday, December 30th. Berenberg Bank lifted their price target on shares of GSK from GBX 1,580 ($19.26) to GBX 1,730 ($21.08) in a research note on Friday, February 10th. Finally, JPMorgan Chase & Co. lifted their price target on shares of GSK from GBX 1,350 ($16.45) to GBX 1,400 ($17.06) in a research note on Thursday, February 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, GSK has an average rating of “Hold” and a consensus price target of $1,576.88.

About GSK

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.